SUBSCRIBE: Print / Digital / eNewsletter
High-grade nonmuscle-invasive bladder cancer is characterized by high rates of disease progression following introduction of bladder-preservation therapy after treatment with Bacillus Calmette-Guérin.
“Histologic subtype shouldn’t exclude patients from getting checkpoint inhibitor therapy,” says Natalie J. Miller, MD, PhD.
The PARP inhibitor olaparib significantly extended radiographic progression-free survival compared with physician’s choice of hormonal therapy in men with metastatic castration-resistant prostate cancer who had defects in genes involved in DNA repair mechanisms.
The first long-term study of an implantable electrode for tibial stimulation to treat overactive bladder shows a sustained high responder rate and a clean safety profile, said Roger R. Dmochowski, MD, at the AUA annual meeting in Chicago.
Treatment for overactive bladder (OAB) improves OAB symptoms similarly in frail and nonfrail older patients with no difference in side effects, according to a multi-institutional study presented at the AUA annual meeting in Chicago.
Adding immunotherapy in the form of atezolizumab (Tecentriq) to platinum-based chemotherapy extends progression-free survival compared with chemotherapy alone in patients with previously untreated metastatic urothelial carcinoma, according to results from a phase III study.
Androgen deprivation therapy for advanced prostate cancer may increase the likelihood of urethral atrophy in men with an artificial urinary sphincter (AUS), thereby contributing to an increased risk of AUS cuff erosion.
On the basis of findings from the KEYNOTE-426 study, the combination of pembrolizumab (KEYTRUDA) plus axitinib (Inlyta) represents a new standard as front-line treatment for metastatic clear cell renal cell carcinoma, said Thomas Powles, MD.
Integration of tumor genetic testing and genomically-informed therapies into clinical practice for patients with advanced prostate cancer are featured in updated National Comprehensive Cancer Network guidelines on the management of prostate cancer (version 2.2019).
Alterations in DNA damage response genes, excluding ATM, correlate with improved outcomes in relapsed/advanced urothelial cancer.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
